Literature DB >> 15725049

Development and validation of a patient satisfaction and preference questionnaire for inhalation devices.

Chris M Kozma1, Terra L Slaton, Brigitta U Monz, Richard Hodder, Pat R Reese.   

Abstract

INTRODUCTION: The Patient Satisfaction and Preference Questionnaire (PASAPQ) is a multi-item measure of respiratory inhalation device satisfaction and preference designed to be easily understood and administered to patients with asthma and COPD. This study assessed its validity, reliability and responsiveness and explored the between-group difference in PASAPQ scores that is meaningful.
METHODS: The field test version was developed using literature, focus groups and expert opinion. Item reduction followed. The assessment of the validity, reliability and responsiveness of the PASAPQ utilized data from two clinical studies comparing devices delivering the same medication, and was performed with pre-specified criteria. A minimally important difference (MID) was estimated using both anchor- and distribution-based approaches.
RESULTS: Two factors of the PASAPQ, 'performance' and 'convenience', were consistent across studies. Missing and out-of-range data were minimal (<1%) and respondents used a full range of response options. All items correlated most highly with their hypothesized scale and all exceeded the minimum correlation criteria of 0.40. Cronbach's alfa was high (0.87-0.94), providing support for internal reliability for the PASAPQ. Correlations of the overall satisfaction item with the performance domain ranged from 0.78 to 0.91, the convenience domain ranged from 0.54 to 0.71, and the total score ranged from 0.78 to 0.90. These moderate-to-strong correlations provide substantial support for the validity of the PASAPQ domains and total score. Discriminate validity was assessed by calculating PASAPQ scores for patients' ratings of the device that they preferred compared with the other, non-preferred device. The preferred device was rated higher on all satisfaction measures, supporting the ability of the PASAPQ to discriminate between preferred and non-preferred devices. Although a difference of 3 or 4 points may be sufficient to observe a small effect difference between groups, most of the MID estimates were in the 8-10 point range. DISCUSSION AND
CONCLUSION: Our analyses across asthma, COPD and patients with mixed respiratory disease (with features of both COPD and asthma), study designs and data sets lead us to conclude that the PASAPQ is a practical, valid, reliable and responsive instrument for measuring respiratory device satisfaction. Furthermore, a difference in satisfaction scores between treatment groups of 10 points is, conservatively, a difference that is meaningful to patients.

Entities:  

Mesh:

Year:  2005        PMID: 15725049     DOI: 10.2165/00151829-200504010-00005

Source DB:  PubMed          Journal:  Treat Respir Med        ISSN: 1176-3450


  29 in total

Review 1.  Treatment satisfaction instruments for different purposes during a product's lifecycle: keeping the end in mind.

Authors:  Diana Rofail; Fiona Taylor; Antoine Regnault; Anna Filonenko
Journal:  Patient       Date:  2011       Impact factor: 3.883

2.  COPD patient satisfaction with ipratropium bromide/albuterol delivered via Respimat: a randomized, controlled study.

Authors:  Gary T Ferguson; Mo Ghafouri; Luyan Dai; Leonard J Dunn
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-03-19

Review 3.  Efficacy and safety of eco-friendly inhalers: focus on combination ipratropium bromide and albuterol in chronic obstructive pulmonary disease.

Authors:  Ralph J Panos
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-04-30

4.  Minimally important difference of the Treatment Satisfaction with Medicines Questionnaire (SATMED-Q).

Authors:  Javier Rejas; Miguel A Ruiz; Antonio Pardo; Javier Soto
Journal:  BMC Med Res Methodol       Date:  2011-10-20       Impact factor: 4.615

5.  Preference, satisfaction and critical errors with Genuair and Breezhaler inhalers in patients with COPD: a randomised, cross-over, multicentre study.

Authors:  Sergi Pascual; Jan Feimer; Anthony De Soyza; Jaume Sauleda Roig; John Haughney; Laura Padullés; Beatriz Seoane; Ludmyla Rekeda; Anna Ribera; Henry Chrystyn
Journal:  NPJ Prim Care Respir Med       Date:  2015-04-30       Impact factor: 2.871

6.  Asthma patients prefer Respimat Soft Mist Inhaler to Turbuhaler.

Authors:  Rick Hodder; Pat Ray Reese; Terra Slaton
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-06-11

Review 7.  Use of Respimat Soft Mist inhaler in COPD patients.

Authors:  Paula Anderson
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

Review 8.  Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhaler.

Authors:  Richard Hodder; David Price
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-10-19

9.  Development of Respimat(®) Soft Mist™ Inhaler and its clinical utility in respiratory disorders.

Authors:  Richard N Dalby; Joachim Eicher; Bernd Zierenberg
Journal:  Med Devices (Auckl)       Date:  2011-09-01

10.  Evaluation of patient preference and willingness to pay for attributes of maintenance medication for chronic obstructive pulmonary disease (COPD).

Authors:  Ariane K Kawata; Leah Kleinman; Gale Harding; Sulabha Ramachandran
Journal:  Patient       Date:  2014       Impact factor: 3.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.